Q2 2025 · 13F-HR
Kynam Capital Management, LPholdings as filed
Filed 2025-08-14 · accession 0001085146-25-005132
$928.8M
Reported value
31
Positions
2025-06-30
Period end
The Brief · Kynam Capital Management, LP · Q2 2025
AI · grounded in 13F
Kynam Capital Management, LP established a new position in CLDX valued at $124.1M. The fund also initiated new stakes in PCVX for $99.9M and VERA for $80.7M. Additional new positions included SNDX at $79.8M and BCRX at $75.8M. The fund ended the period with 31 positions and total AUM of $928.8M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $124.1M | 13.4% | 6,100,729 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $99.9M | 10.8% | 3,071,588 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $80.7M | 8.69% | 3,426,887 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $79.8M | 8.59% | 8,520,000 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $75.8M | 8.16% | 8,463,742 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $63.9M | 6.88% | 2,457,667 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $61.9M | 6.66% | 4,427,927 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $61.0M | 6.56% | 8,492,557 | Common | SOLE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC | $41.1M | 4.43% | 2,417,647 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $30.6M | 3.30% | 976,267 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $29.6M | 3.19% | 4,560,053 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $22.8M | 2.45% | 1,540,691 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $22.3M | 2.40% | 2,329,998 | Common | SOLE |
| 268158201 | DVAX | DYNAVAX TECHNOLOGIES CORP | $21.3M | 2.29% | 2,145,319 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $18.2M | 1.96% | 4,994,090 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $15.8M | 1.70% | 2,095,998 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $13.4M | 1.44% | 1,173,605 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $10.0M | 1.08% | 2,887,014 | Common | SOLE |
| 023111404 | AMRN | AMARIN CORP PLC | $9.3M | 1.01% | 576,111 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $9.0M | 0.97% | 656,573 | Common | SOLE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $4.9M | 0.53% | 2,154,413 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $4.9M | 0.52% | 3,456,318 | Common | SOLE |
| 46333X108 | IRWD | IRONWOOD PHARMACEUTICALS INC | $3.9M | 0.42% | 5,466,825 | Common | SOLE |
| 142038108 | CRBU | CARIBOU BIOSCIENCES INC | $3.9M | 0.42% | 3,067,774 | Common | SOLE |
| 869367102 | STRO | SUTRO BIOPHARMA INC | $3.6M | 0.39% | 5,088,099 | Common | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $3.5M | 0.37% | 1,029,579 | Common | SOLE |
| N71542109 | PRQR | PROQR THRAPEUTICS N V | $3.4M | 0.36% | 1,649,462 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $3.3M | 0.36% | 253,979 | Common | SOLE |
| 12233L206 | BNR | BURNING ROCK BIOTECH LTD | $3.1M | 0.34% | 994,883 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $2.5M | 0.27% | 200,047 | Common | SOLE |
| 28658R106 | CLYM | CLIMB BIO INC | $1.3M | 0.14% | 1,028,341 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.